The Non-Hodgkin’s Lymphoma Drug Market Will More Than Double, Increasing from Approximately $4 Billion in 2009 to $8.4 Bil

However, Growth Will Be Tempered By the Entry of Biosimilar Versions of Rituximab in 2013 in Europe and in 2015 in the U.S., According to Findings from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven by the launches of premium-priced therapies, the non-Hodgkin’s lymphoma drug market will more than double over the next decade, increasing from approximately $4 billion in 2009 to $8.4 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The findings from the Pharmacor topic entitled Non-Hodgkin’s Lymphoma also reveal that market growth will be tempered by the entry of biosimilar versions of rituximab (Roche/Genentech/Chugai Seiyaku/Zenyaku Kogyo’s Rituxan/MabThera) in 2013 in Europe and in 2015 in the United States. Biosimilar rituximab will be priced lower than branded rituximab and—as a result of the widespread uptake of rituximab across all non-Hodgkin’s lymphoma populations—the entry of biosimilars will cause a significant drop in the sales of branded rituximab.

“Despite the entrance of biosimilars, rituximab will maintain its dominance as the market-leading agent through 2019,” said Decision Resources Director Andrew Merron, Ph.D. “In an attempt to reduce the negative impact of biosimilar erosion on branded rituximab, Roche has developed a novel anti-CD20 antibody—GA-101—and a subcutaneous formulation of rituximab that should help soften the anticipated drop in sales of branded, intravenously delivered rituximab.”

Although little new commercial opportunity remains for rituximab in non-Hodgkin’s lymphoma, its sales will increase through 2014 as its uptake continues to grow in the first-line maintenance setting for follicular lymphoma and as a single agent for newly diagnosed asymptomatic follicular lymphoma. Sales of GlaxoSmithKline/Genmab’s Arzerra will also increase as a result of greater use in the wider non-Hodgkin’s lymphoma patient population.

The findings also reveal that Celgene’s Revlimid (an agent already widely used in multiple myeloma) and two novel kinase inhibitors, Pharmacyclics’ PCI-32765 and Calistoga Pharmaceuticals’ CAL-101 are generating excitement amongst key opinion leaders and together will contribute to significant sales growth in the non-Hodgkin’s lymphoma drug market, following their expected launches beginning in 2014.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

After seeing later stage trials come through in obesity, Novo Nordisk is canning two projects that were aiming to help reduce patients’ weight.

T-knife has raised €66 million ($78 million) to take four prospects from its TCR-T-cell platform into the clinic in solid tumor indications.

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.